Investing.com - Editas Medicine (NASDAQ: EDIT) reported fourth quarter EPS of $-0.23, $0.36 better than the analyst estimate of $-0.59. Revenue for the quarter came in at $60.04M versus the consensus estimate of $3.7M.
Editas Medicine's stock price closed at $8.86. It is down -17.73% in the last 3 months and up 1.61% in the last 12 months.
Editas Medicine saw 5 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Editas Medicine's stock price’s past reactions to earnings here.
According to InvestingPro, Editas Medicine's Financial Health score is "fair performance".
Check out Editas Medicine's recent earnings performance, and Editas Medicine's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar